Treating Type 1 Diabetes by Pancreas Transplant Alone: A Cohort Study on Actual Long-term (10 Years) Efficacy and Safety.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
29
4
2021
medline:
29
3
2022
entrez:
28
4
2021
Statut:
ppublish
Résumé
Physiologically regulated insulin secretion and euglycemia are achievable in type 1 diabetes (T1D) by islet or pancreas transplantation. However, pancreas transplant alone (PTA) remains a debated approach, with uncertainties on its relative benefits and risks. We determined the actual long-term (10 y) efficacy and safety of PTA in carefully characterized T1D subjects. This is a single-center, cohort study in 66 consecutive T1D subjects who received a PTA between April 2001 and December 2007, and were then all followed until 10 y since transplant. Main features evaluated were patient survival, pancreas graft function, C-peptide levels, glycemic parameters, and the function of the native kidneys. Ten-year actual patient survival was 92.4%. Optimal (insulin independence) or good (minimal insulin requirement) graft function was observed in 57.4% and 3.2% of patients, respectively. Six (9.0%) patients developed stage 5 or 4 chronic kidney disease. In the remaining individuals bearing a successful PTA, estimated glomerular filtration rate (eGFR) decline per year was -2.29 ± 2.69 mL/min/1.73 m2. Reduction of eGFR at 1 y post-PTA was higher in those with pre-PTA hyperfiltration and higher HbA1c concentrations; eGFR changes afterward significantly correlated with diabetes duration. In recipients with normoglycemia at 10 y, 74% of normoalbuminuric or microalbuminuric subjects pre-PTA remained stable, and 26% progressed toward a worse stage; conversely, in 62.5% of the macroalbuminuric individuals albuminuria severity regressed. These long-term effects of PTA on patient survival, graft function, and the native kidneys support PTA as a suitable approach to treat diabetes in selected T1D patients.
Sections du résumé
BACKGROUND
Physiologically regulated insulin secretion and euglycemia are achievable in type 1 diabetes (T1D) by islet or pancreas transplantation. However, pancreas transplant alone (PTA) remains a debated approach, with uncertainties on its relative benefits and risks. We determined the actual long-term (10 y) efficacy and safety of PTA in carefully characterized T1D subjects.
METHODS
This is a single-center, cohort study in 66 consecutive T1D subjects who received a PTA between April 2001 and December 2007, and were then all followed until 10 y since transplant. Main features evaluated were patient survival, pancreas graft function, C-peptide levels, glycemic parameters, and the function of the native kidneys.
RESULTS
Ten-year actual patient survival was 92.4%. Optimal (insulin independence) or good (minimal insulin requirement) graft function was observed in 57.4% and 3.2% of patients, respectively. Six (9.0%) patients developed stage 5 or 4 chronic kidney disease. In the remaining individuals bearing a successful PTA, estimated glomerular filtration rate (eGFR) decline per year was -2.29 ± 2.69 mL/min/1.73 m2. Reduction of eGFR at 1 y post-PTA was higher in those with pre-PTA hyperfiltration and higher HbA1c concentrations; eGFR changes afterward significantly correlated with diabetes duration. In recipients with normoglycemia at 10 y, 74% of normoalbuminuric or microalbuminuric subjects pre-PTA remained stable, and 26% progressed toward a worse stage; conversely, in 62.5% of the macroalbuminuric individuals albuminuria severity regressed.
CONCLUSIONS
These long-term effects of PTA on patient survival, graft function, and the native kidneys support PTA as a suitable approach to treat diabetes in selected T1D patients.
Identifiants
pubmed: 33909390
pii: 00007890-202201000-00031
doi: 10.1097/TP.0000000000003627
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-157Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14–S31.
Bleich D, Wagner DH. Challenges to reshape the future of type 1 diabetes research. J Clin Endocrinol Metab. 2018;103:2838–2842.
Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab Res Rev. 2009;25:99–111.
Battelino T, Omladič JŠ, Phillip M. Closed loop insulin delivery in diabetes. Best Pract Res Clin Endocrinol Metab. 2015;29:315–325.
Skyler JS. Hope vs hype: where are we in type 1 diabetes? Diabetologia. 2018;61:509–516.
Bjornstad P, Donaghue KC, Maahs DM. Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment? Lancet Diabetes Endocrinol. 2018;6:809–820.
Morgan E, Cardwell CR, Black CJ, et al. Excess mortality in type 1 diabetes diagnosed in childhood and adolescence: a systematic review of population-based cohorts. Acta Diabetol. 2015;52:801–807.
Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg. 2001;233:463–501.
Larsen JL. Pancreas transplantation: indications and consequences [published correction appears in Endocr Rev . 2005;26(5):661]. Endocr Rev. 2004;25:919–946.
Rickels MR, Peleckis AJ, Markmann E, et al. Long-term improvement in glucose control and counterregulation by islet transplantation for type 1 diabetes. J Clin Endocrinol Metab. 2016;101:4421–4430.
Lablanche S, Vantyghem MC, Kessler L, et al.; TRIMECO trial investigators. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:527–537.
Shapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017;13:268–277.
Coppelli A, Giannarelli R, Vistoli F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care. 2005;28:1366–1370.
Gremizzi C, Vergani A, Paloschi V, et al. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant. 2010;15:119–123.
Giannarelli R, Coppelli A, Sartini MS, et al. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia. 2006;49:2977–2982.
Occhipinti M, Rondinini L, Mariotti R, et al. Amelioration of cardiac morphology and function in type 1 diabetic patients with sustained success of pancreas transplant alone. Diabetes Care. 2014;37:e171–e172.
Pellegrini S, Cantarelli E, Sordi V, et al. The state of the art of islet transplantation and cell therapy in type 1 diabetes. Acta Diabetol. 2016;53:683–691.
Fiorina P, Shapiro AM, Ricordi C, et al. The clinical impact of islet transplantation. Am J Transplant. 2008;8:1990–1997.
Boggi U, Amorese G, Marchetti P. Surgical techniques for pancreas transplantation. Curr Opin Organ Transplant. 2010;15:102–111.
Sharples EJ, Mittal SM, Friend PJ. Challenges in pancreas transplantation. Acta Diabetol. 2016;53:871–878.
Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61:827–837.
Gruessner AC, Gruessner RWG. Pancreas transplantation for patients with type 1 and type 2 diabetes mellitus in the United States: a registry report. Gastroenterol Clin North Am. 2018;47:417–441.
Kandaswamy R, Stock PG, Gustafson SK, et al. OPTN/SRTR 2015 annual data report: pancreas. Am J Transplant. 2017;17(Suppl 1):117–173.
White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet. 2009;373:1808–1817.
Robertson RP, Davis C, Larsen J, et al.; American Diabetes Association. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care. 2006;29:935.
Choudhary P, Rickels MR, Senior PA, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care. 2015;38:1016–1029.
Gruessner RW, Gruessner AC. Pancreas transplant alone: a procedure coming of age. Diabetes Care. 2013;36:2440–2447.
Stratta RJ, Gruessner AC, Odorico JS, et al. Pancreas transplantation: an alarming crisis in confidence. Am J Transplant. 2016;16:2556–2562.
Rickels MR, Stock PG, de Koning EJP, et al. Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop. Transpl Int. 2018;31:343–352.
Boggi U, Vistoli F, Amorese G, et al. Long-term (5 years) efficacy and safety of pancreas transplantation alone in type 1 diabetic patients. Transplantation. 2012;93:842–846.
Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate [published correction appears in Ann Intern Med . 2008;149(7):519]. Ann Intern Med. 2006;145:247–254.
Miller WG, Bruns DE, Hortin GL, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem. 2009;55:24–38.
Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150:252–259.
Secrest AM, Becker DJ, Kelsey SF, et al. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care. 2010;33:2573–2579.
Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–1982.
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39:1378–1383.
Gagnum V, Stene LC, Leivestad T, et al. Long-term mortality and end-stage renal disease in a type 1 diabetes population diagnosed at age 15-29 years in Norway. Diabetes Care. 2017;40:38–45.
Secrest AM, Becker DJ, Kelsey SF, et al. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59:3216–3222.
Cartwright A, Wallymahmed M, Macfarlane IA, et al. The outcome of brittle type 1 diabetes–a 20 year study. QJM. 2011;104:575–579.
Youssef NCM, Reinhart F, Sakr Y. The pros and cons of multicentre studies. Neth J Crit Care. 2008;12:120–122.
Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12:1576–1583.
Oliver JB, Beidas AK, Bongu A, et al. A comparison of long-term outcomes of portal versus systemic venous drainage in pancreatic transplantation: a systematic review and meta-analysis. Clin Transplant. 2015;29:882–892.
Siskind E, Amodu L, Liu C, et al. A comparison of portal venous versus systemic venous drainage in pancreas transplantation. HPB (Oxford). 2019;21:195–203.
Bazerbachi F, Selzner M, Boehnert MU, et al. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation. 2011;92:1039–1043.
Fernández-Burgos I, Montiel Casado MC, Pérez-Daga JA, et al. Induction therapy in simultaneous pancreas-kidney transplantation: thymoglobulin versus basiliximab. Transplant Proc. 2015;47:120–122.
Amorese G, Lombardo C, Tudisco A, et al. Induction and immunosuppressive management of pancreas transplant recipients. Curr Pharm Des. 2020;26:3425–3439.
Niclauss N, Meier R, Bédat B, et al. Beta-cell replacement: pancreas and islet cell transplantation. Endocr Dev. 2016;31:146–162.
Jalbert M, Zheng F, Wojtusciszyn A, et al.; TRIMECO Study Group. Glycemic variability indices can be used to diagnose islet transplantation success in type 1 diabetic patients. Acta Diabetol. 2020;57:335–345.
Vantyghem MC, Chetboun M, Gmyr V, et al. Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: a prospective parallel-arm cohort study [published correction appears in Diabetes Care . 2020 May;43(5):1164]. Diabetes Care. 2019;42:2042–2049.
Kumano K, Lawrence MC, Onaca N, et al. Successful allogeneic islet transplantation after total pancreatectomy with islet autotransplantation to restore normoglycemia: a case report. Acta Diabetol. 2020;57:619–622.
Rickels MR, Robertson RP. Pancreatic islet transplantation in humans: recent progress and future directions. Endocr Rev. 2019;40:631–668.
Boggi U, Rosati CM, Marchetti P. Follow-up of secondary diabetic complications after pancreas transplantation. Curr Opin Organ Transplant. 2013;18:102–110.
Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.
Kreis H. New strategies to reduce nephrotoxicity. Transplantation. 2001;72(12 Suppl):S99–104.
Hošková L, Málek I, Kopkan L, et al. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. Physiol Res. 2017;66:167–180.
Kim SJ, Smail N, Paraskevas S, et al. Kidney function before pancreas transplant alone predicts subsequent risk of end-stage renal disease. Transplantation. 2014;97:675–680.
Singh SK, Kim SJ, Smail N, et al. Outcomes of recipients with pancreas transplant alone who develop end-stage renal disease. Am J Transplant. 2016;16:535–540.
Skupien J, Warram JH, Smiles AM, et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 2012;82:589–597.
Skupien J, Warram JH, Smiles AM, et al. Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes. Diabetes Care. 2016;39:2262–2269.
Ponticelli C, Glassock RJ. Prevention of complications from use of conventional immunosuppressants: a critical review. J Nephrol. 2019;32:851–870.
Gijsen VM, Madadi P, Dube MP, et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant. 2012;17:111–121.
Odorico JS, Voss B, Munoz Del Rio A, et al. Kidney function after solitary pancreas transplantation. Transplant Proc. 2008;40:513–515.
Remuzzi A, Viberti G, Ruggenenti P, et al. Glomerular response to hyperglycemia in human diabetic nephropathy. Am J Physiol. 1990;259(4 Pt 2):F545–F552.
Miller RG, Orchard TJ. Understanding metabolic memory: a tale of two studies. Diabetes. 2020;69:291–299.
Venstrom JM, McBride MA, Rother KI, et al. Survival after pancreas transplantation in patients with diabetes and preserved kidney function [published correction appears in JAMA . 2004;291(13):1566]. JAMA. 2003;290:2817–2823.